ArticleInternal medicine journal2026
Clinical characteristics of autoimmune glial fibrillary acidic protein astrocytopathy in adults: a retrospective analysis of 9 cases.
Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo identify early diagnostic clues, we analysed cerebrospinal fluid and serum biomarkers in patients with autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) and compared biomarker trends with those in patients with viral meningoencephalitis, tuberculous meningoencephalitis, and anti-N-methyl-D-aspartate receptor encephalitis.
methodsNine GFAP-A patients were retrospectively enrolled from the First Affiliated Hospital, Zhejiang University School of Medicine, between January 2021 and January 2022. We evaluated the clinical manifestations, laboratory findings, neuroimaging, electroencephalography, treatment and prognosis of these adult GFAP-A cases. Cerebrospinal fluid and serum biomarker trends were compared across the GFAP-A, viral meningoencephalitis, tuberculous meningoencephalitis and anti-N-methyl-D-aspartate receptor encephalitis groups.
resultsAll nine patients presented with acute or subacute onset of meningeal and/or encephalitic symptoms. Brain magnetic resonance imaging revealed lesions predominantly affecting the subcortical white matter, basal ganglia, occipital lobe, brain stem, ventricles, cerebellum and corpus callosum. Each patient achieved a modified Rankin Scale score of 0-2, and no recurrence was observed during the 6-month follow-up period.
conclusionDifferentiating GFAP-A from anti-N-methyl-D-aspartate receptor encephalitis based on conventional inflammatory biomarkers remains challenging. Elevated serum C-reactive protein and procalcitonin levels are more suggestive of viral or tuberculous meningoencephalitis. GFAP-A is generally associated with a favourable prognosis and no recurrence within 6 months of follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.